company background image
COPN

Cosmo Pharmaceuticals SWX:COPN Stock Report

Last Price

CHF47.50

Market Cap

CHF778.2m

7D

7.3%

1Y

-34.6%

Updated

04 Oct, 2022

Data

Company Financials +
COPN fundamental analysis
Snowflake Score
Valuation5/6
Future Growth6/6
Past Performance3/6
Financial Health4/6
Dividends1/6

COPN Stock Overview

Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology and endoscopy worldwide.

Cosmo Pharmaceuticals N.V. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Cosmo Pharmaceuticals
Historical stock prices
Current Share PriceCHF47.50
52 Week HighCHF76.50
52 Week LowCHF42.30
Beta1.01
1 Month Change-8.48%
3 Month Change-2.16%
1 Year Change-34.57%
3 Year Change-39.41%
5 Year Change-68.33%
Change since IPO113.00%

Recent News & Updates

Mar 31
Cosmo Pharmaceuticals' (VTX:COPN) Solid Profits Have Weak Fundamentals

Cosmo Pharmaceuticals' (VTX:COPN) Solid Profits Have Weak Fundamentals

Cosmo Pharmaceuticals N.V. ( VTX:COPN ) announced strong profits, but the stock was stagnant. We did some digging, and...

Shareholder Returns

COPNCH PharmaceuticalsCH Market
7D7.3%4.1%4.1%
1Y-34.6%1.1%-12.8%

Return vs Industry: COPN underperformed the Swiss Pharmaceuticals industry which returned -0.7% over the past year.

Return vs Market: COPN underperformed the Swiss Market which returned -15% over the past year.

Price Volatility

Is COPN's price volatile compared to industry and market?
COPN volatility
COPN Average Weekly Movement4.1%
Pharmaceuticals Industry Average Movement5.5%
Market Average Movement4.4%
10% most volatile stocks in CH Market7.6%
10% least volatile stocks in CH Market2.2%

Stable Share Price: COPN is not significantly more volatile than the rest of Swiss stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: COPN's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1997292Alessandro Della Chahttps://www.cosmopharma.com

Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology and endoscopy worldwide. It offers Lialda/Mezavant/Mesavancol and UCERIS/Cortiment, an oral tablet formulation for remission in active, mild to moderate ulcerative colitis; GI Genius, a system that uses artificial intelligence to detect colorectal polyps; and Methylene Blue MMX, diagnostic drug to enhance pre-cancerous and cancerous detection of colorectal lesions during colonoscopy. The company also provides Eleview, an injectable composition for use in gastrointestinal endoscopic procedures for submucosal lift of polyps, adenomas, early-stage cancers, or other gastrointestinal mucosal lesions; Aemcolo/Relafalk, a pharmaceutical product used for the treatment of traveler’s diarrhea, uncomplicated acute diverticulitis, minimal hepatic encephalopathy, and small intestine bacterial overgrowth; and Winlevi, an androgen receptor inhibitor for acne vulgaris.

Cosmo Pharmaceuticals N.V. Fundamentals Summary

How do Cosmo Pharmaceuticals's earnings and revenue compare to its market cap?
COPN fundamental statistics
Market CapCHF778.22m
Earnings (TTM)CHF34.45m
Revenue (TTM)CHF76.32m

22.6x

P/E Ratio

10.2x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
COPN income statement (TTM)
Revenue€78.17m
Cost of Revenue€36.40m
Gross Profit€41.76m
Other Expenses€6.48m
Earnings€35.28m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)2.15
Gross Margin53.43%
Net Profit Margin45.14%
Debt/Equity Ratio36.1%

How did COPN perform over the long term?

See historical performance and comparison

Dividends

2.0%

Current Dividend Yield

48%

Payout Ratio